# ABL103 in Combination With Pembrolizumab, With or Without Taxane in Advanced or Metastatic Solid Tumors

> **NCT07158918** · PHASE1,PHASE2 · RECRUITING · sponsor: **ABL Bio, Inc.** · enrollment: 65 (estimated)

## Conditions studied

- Solid Tumors

## Interventions

- **DRUG:** ABL103
- **DRUG:** KEYTRUDA® (pembrolizumab)
- **DRUG:** Taxane

## Key facts

- **NCT ID:** NCT07158918
- **Lead sponsor:** ABL Bio, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-08-06
- **Primary completion:** 2027-12-02
- **Final completion:** 2027-12-02
- **Target enrollment:** 65 (ESTIMATED)
- **Last updated:** 2025-09-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07158918

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07158918, "ABL103 in Combination With Pembrolizumab, With or Without Taxane in Advanced or Metastatic Solid Tumors". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT07158918. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*